BioPharma Dive
1,426 FOLLOWERS
BioPharma Dive is a leading industry publication providing in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing, and M&A to research partnerships.
BioPharma Dive
7h ago
Interim data surpassed expectations, iTeos said. Elsewhere, Acelyrin revealed chief executive officer Shao-Lee Lin is departing and Bluebird bio gave a fuller account of its gene therapy launches ..read more
BioPharma Dive
7h ago
The regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said ..read more
BioPharma Dive
7h ago
An alliance with Shionogi involves similar terms as a deal Sanofi canceled in response to an unusual challenge from the Federal Trade Commission ..read more
BioPharma Dive
7h ago
Sanofi will ally with the under-pressure biotech, paying $500 million upfront for rights to co-commercialize Novavax’s COVID shot and develop combination influenza vaccines ..read more
BioPharma Dive
1d ago
The company is discontinuing an array of early drug programs, including several in oncology, as it prioritizes investment in six late-stage assets ..read more
BioPharma Dive
1d ago
The deal gives the company milestone payments and royalties to a medicine, frexalimab, that Sanofi licensed from biotech ImmuNext and expects to be a future blockbuster ..read more
BioPharma Dive
1d ago
The deal with Metaphore Biotechnologies is the third to emerge from a Flagship alliance that’s meant to boost the Danish drugmaker’s pipeline of weight loss medicines ..read more
BioPharma Dive
2d ago
Intellectual property is the foundation of the drug industry’s business model. This database will track key patent expiry dates for 30 top-selling medicines ..read more
BioPharma Dive
2d ago
The move ends a turbulent saga for AstraZeneca, which successfully developed a coronavirus shot but struggled to sell it amid competition and the emergence of rare but serious side effects. ..read more
BioPharma Dive
2d ago
The results add to an early but growing body of evidence suggesting gene therapy may improve outcomes in young kids with a genetic form of deafness. ..read more